Jefferies Financial Group Lowers Danaher (NYSE:DHR) Price Target to $260.00

Danaher (NYSE:DHR) had its price objective cut by equities research analysts at Jefferies Financial Group from $285.00 to $260.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the conglomerate’s stock. Jefferies Financial Group’s price target would indicate a potential upside of 16.53% from the stock’s previous close.

Several other analysts also recently weighed in on DHR. Scotiabank initiated coverage on Danaher in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price objective for the company. Barclays decreased their target price on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Stephens reaffirmed an “overweight” rating and issued a $315.00 price target on shares of Danaher in a research note on Wednesday, October 23rd. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a research note on Thursday, October 31st. Finally, Citigroup reduced their price target on Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Six investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $284.14.

Danaher Price Performance

NYSE:DHR traded down $24.72 during mid-day trading on Wednesday, reaching $223.12. The stock had a trading volume of 11,388,171 shares, compared to its average volume of 3,455,745. The firm has a 50 day moving average price of $236.09 and a two-hundred day moving average price of $253.66. The stock has a market capitalization of $161.15 billion, a P/E ratio of 42.58, a P/E/G ratio of 4.43 and a beta of 0.83. Danaher has a one year low of $223.00 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37.

Danaher (NYSE:DHR) last released its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. During the same period in the prior year, the business posted $2.09 earnings per share. As a group, analysts expect that Danaher will post 7.5 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Marks Group Wealth Management Inc lifted its holdings in Danaher by 6.7% in the fourth quarter. Marks Group Wealth Management Inc now owns 4,972 shares of the conglomerate’s stock valued at $1,141,000 after acquiring an additional 312 shares during the period. Great Lakes Retirement Inc. raised its stake in shares of Danaher by 1.5% in the fourth quarter. Great Lakes Retirement Inc. now owns 37,002 shares of the conglomerate’s stock worth $8,494,000 after buying an additional 542 shares during the period. Kentucky Trust Co bought a new position in shares of Danaher in the fourth quarter worth about $34,000. Gladstone Institutional Advisory LLC raised its stake in shares of Danaher by 21.8% in the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,510 shares of the conglomerate’s stock worth $806,000 after buying an additional 628 shares during the period. Finally, Certuity LLC raised its stake in shares of Danaher by 18.3% in the fourth quarter. Certuity LLC now owns 1,293 shares of the conglomerate’s stock worth $297,000 after buying an additional 200 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.